Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.
Currently unavailable
This product is listed for research reference. It is not currently available for ordering. Live alternatives from the same research category are shown below.
This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.
Notify me when availableNeed the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
Available now
These products from the same research category are currently available for ordering.
How it works
MOD GRF 1-29 activates GHRH receptors on pituitary somatotropes with full agonism, producing pulsatile GH release via cAMP signaling. Four protective substitutions extend half-life from ~2 min to ~30 min by blocking DPP-IV and neutral endopeptidase cleavage. Synergistic with GHS-R1a agonists (ipamorelin) through mechanistically independent GH amplification.
Compound profile
Product definition
MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.
MOD GRF 1-29 is the pharmacological name for the tetrasubstituted GHRH(1-29) peptide. The 'MOD' prefix indicates the four protective modifications: Aib at position 2 (DPP-IV resistance), Gln at position 8 (neutral endopeptidase protection), Ala at position 15 (backbone stability), and Nle at position 27 (methionine oxidation prevention). These modifications are collectively responsible for the pharmacokinetic improvement versus native GHRH while preserving receptor binding and signaling. The compound is also commercially designated CJC-1295 Without DAC — the same peptide referenced by the ConjuChem nomenclature used in research supply contexts. For researchers cross-referencing the pharmacological literature versus commercial product catalogs, MOD GRF 1-29 and CJC-1295 Without DAC are fully interchangeable terms for the same molecule. In the GH secretagogue research literature, MOD GRF 1-29 is studied both as a standalone GHRH agonist (characterizing GHRH receptor pharmacology) and in combination with GHRPs (characterizing the synergistic GHRH+GHRP GH amplification effect). Its 30-minute half-life and preserved pulsatile kinetics make it the default short-acting GHRH reference compound.
Research audience
MOD GRF 1-29 is used by researchers in GH axis pharmacology, GHRH receptor biology, pituitary somatotrope function, and GH secretagogue combination research. It is the standard GHRH component for researchers who are cross-referencing pharmacological literature (where 'MOD GRF 1-29' is the primary designation) with commercial research supply sources.
Research context
The pharmacological development of MOD GRF 1-29 represents the systematic application of protective amino acid substitution technology to native GHRH(1-29) — the same approach used in semaglutide (position-8 Aib substitution for DPP-IV resistance) applied to the GHRH scaffold. The specific substitutions were chosen based on known enzymatic cleavage sites in native GHRH: DPP-IV cleavage at His-Ala at positions 1-2, neutral endopeptidase action at position 8, and oxidative methionine degradation at position 27. In GH pulse biology research, MOD GRF 1-29 is used to study how GHRH receptor activation patterns affect somatotrope GH secretion. The pulsatile kinetics (on for ~30 min, then cleared) allow researchers to characterize the GH response to a defined, time-limited GHRH receptor stimulus — useful for studies of somatotrope desensitization, GHRH receptor downregulation, and the pulse frequency effects on downstream IGF-1. For combination GHRH+GHRP research (the 2X Blend design), MOD GRF 1-29 is the GHRH component that pairs with ipamorelin. The mechanistic model is: GHRH receptor activation recruits additional somatotropes and increases their responsiveness (the 'priming' effect); GHS-R1a activation by ipamorelin then produces a larger GH release from the primed pool. The result is a synergistic GH pulse that exceeds either compound alone.
Common questions
You might also want to check out these products.
2X Blend CJC-1295 Without DAC / Ipamorelin
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
CJC-1295 Without DAC
CJC-1295 Without DAC (MOD GRF 1-29) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the preferred short-acting GHRH analog for pulsatile GH research protocols, commonly paired with ipamorelin.
CJC-1295 With DAC
$25.00
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
GHRP-6 Acetate
GHRP-6 is a hexapeptide GHS-R1a agonist and the founding GHRP compound — studied in preclinical models for GH release, significant appetite stimulation, and cortisol co-stimulation via ghrelin receptor activation.
Ipamorelin
$12.00
Ipamorelin is a selective pentapeptide GHRP studied in preclinical models for GH release without cortisol or prolactin elevation — the most selective GHRP in its class.
IGF-1LR3
$30.00
IGF-1 LR3 is an 83-amino-acid IGF-1 analog with reduced IGFBP binding, extending half-life from ~15 minutes to ~20–30 hours — the most studied long-acting IGF-1 analog in preclinical research.
Hexarelin Acetate
Hexarelin (Examorelin) is the most potent characterized GHRP hexapeptide — GHS-R1a agonist with Phase II human data and unique CD36 cardiac receptor binding providing GH-independent cardioprotection in animal models.
IGF-DES
Tesamorelin
$29.00
Tesamorelin is a 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification — the only FDA-approved GHRH peptide, validated in Phase III trials for visceral adiposity reduction.
Sermorelin
Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.
GHRP-2
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist approved in Japan for GH stimulation testing — a potent non-selective GHRP that stimulates GH alongside cortisol and prolactin.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy